Vanguard Investments Australia’s KalVista Pharmaceuticals KALV Stock Holding History

Vanguard Investments Australia’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$174K	Buy	+8,650	New	+$139K	﹤0.01%	2101

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Investments Australia's KALV Position: Q1 2026 in Review

Vanguard Investments Australia opened a new position in KalVista Pharmaceuticals (KALV) in Q1 2026: 8,650 shares worth $174K. The stake represents ﹤0.01% of the portfolio and ranks #2101 among its holdings.

183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Vanguard Investments Australia held 8,650 shares of KalVista Pharmaceuticals worth $174K as of Q1 2026.
KalVista Pharmaceuticals was a new Vanguard Investments Australia position in Q1 2026.
KalVista Pharmaceuticals made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q1 2026, its #2101 holding.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Vanguard Investments Australia's 13F filing for Q1 2026, filed 8 May 2026.